SPC439
BCMA (CD269/TNFRSF17) - MÓTEFNAVAKABINDANDI PRÓTEIN
:
Umsókn:
7.9.2023:
15.10.2023
:
24.8.2035:
Blenrep
7.9.2023
15.10.2023
24.8.2035
:
EU/1/20/1474/001:
25.8.2020
:
Glaxo Group Limited:
GSK Medicines Research Centre Gunnels Wood Road, Stevenage SG1 2NY GB
:
Tego IP ehf.:
Pósthólf 8129, 128 Reykjavík